XML 41 R31.htm IDEA: XBRL DOCUMENT
v3.23.3

Description of Business (Tables) | 3 Months Ended
--- | ---
Oct. 31, 2023
Description of Business [Abstract] |
Schedule of All Majority-Owned Subsidiaries are Consolidated | All majority-owned subsidiaries are consolidated with all intercompany transactions and balances eliminated in consolidation. In addition to Rafael Holdings, Inc., the subsidiaries included in these consolidated financial statements are as follows:
Company |  | Country of Incorporation |  | Percentage Owned |
Broad Atlantic Associates, LLC |  | United States – Delaware |  |  | 100 | %
IDT R.E. Holdings Ltd. |  | Israel |  |  | 100 | %
Rafael Holdings Realty, Inc. |  | United States – Delaware |  |  | 100 | %
Barer Institute, Inc. |  | United States – Delaware |  |  | 100 | %*
Hillview Avenue Realty, JV |  | United States – Delaware |  |  | 100 | %
Hillview Avenue Realty, LLC |  | United States – Delaware |  |  | 100 | %
Rafael Medical Devices, LLC |  | United States – Delaware |  |  | 68 | %*****
Levco Pharmaceuticals Ltd. |  | Israel |  |  | 95 | %***
Farber Partners, LLC |  | United States – Delaware |  |  | 93 | %
Pharma Holdings, LLC |  | United States – Delaware |  |  | 90 | %
LipoMedix Pharmaceuticals Ltd. |  | Israel |  |  | 95 | %****
Altira Capital & Consulting, LLC |  | United States – Delaware |  |  | 67 | %
CS Pharma Holdings, LLC |  | United States – Delaware |  |  | 45 | %**
| * | In November 2022, the Company resolved to curtail its early-stage development efforts, including pre-clinical research at Barer. The decision was taken to reduce spending as the Company focuses on exploring strategic opportunities.
| ** | 50% of CS Pharma Holdings, LLC is owned by Pharma Holdings, LLC. We have a 90% ownership in Pharma Holdings, LLC and, therefore, an effective 45% interest in CS Pharma Holdings, LLC. The Company, along with CS Pharma and Pharma Holdings, collectively own securities representing 51% of the outstanding capital stock of Cornerstone Pharmaceuticals and 42% of the capital stock on a fully diluted basis. Refer to Note 4 for further details.
| *** | During Fiscal 2022, the Company discontinued further material investment in Levco. In August 2023, Levco was dissolved.
| **** | On February 9, 2023, the Company increased its ownership interest in LipoMedix Pharmaceuticals Ltd. from 84% to 95%.
| ***** | In August 2023, the Company raised $925,000 from third parties in exchange for 31.62% ownership of Rafael Medical Devices. As of July 31, 2023, the Company recorded $825,000 of the funds received related to the sale within prepaid expenses and other current assets and other liabilities within the consolidated balance sheets.

X
- Definition Schedule of all majority-owned subsidiaries are consolidated. + References No definition available. + Details
Name: | rfl_ScheduleOfAllMajorityOwnedSubsidiariesAreConsolidatedTableTextBlock
Namespace Prefix: | rfl_
Data Type: | dtr:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- References No definition available. + Details
Name: | us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration